Want to join the conversation?
$ENTA announced data showing patients with genotype 1 chronic HCV infection who received recommended regimen of $ABBV's VIEKIRAX EXVIERA achieved high sustained virologic response rates at 48 weeks post-treatment. $ENTA's lead protease inhibitor, Paritaprevir, is one of the direct-acting antivirals in the VIEKIRAX EXVIERA treatment regimen.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.